Summary
Antibe Therapeutics Inc (Antibe) is a pharmaceutical company that designs and develops safer medications for chronic pain and inflammation, besides tissue regeneration products. The company discovers and commercialize novel drugs, biologics and medical devices. It offers ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, aims at meeting the global requirement for a safer non-steroidal anti-inflammatory drug (NSAID). Antibe’s other products comprise ATB-352 for gout, dysmenorrhea, dental pain, post-surgical pain, and ATB-340 for clotting disorders and cancer. The company operates in the US, and other European, the Middle East and Asian countries. Antibe is headquartered in Toronto, Ontario, Canada.
Antibe Therapeutics Inc (ATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 11
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 11
Equity Offering 12
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 12
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 13
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 15
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 16
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 17
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 18
Antibe Therapeutics Completes IPO For US$3 Million 19
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 20
Debt Offering 21
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 21
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 22
Antibe Therapeutics Inc - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 11
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 11
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 12
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 13
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 15
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 16
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 17
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 18
Antibe Therapeutics Completes IPO For US$3 Million 19
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 20
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 21
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 22
Antibe Therapeutics Inc, Key Competitors 24
Antibe Therapeutics Inc, Key Employees 25
Antibe Therapeutics Inc, Subsidiaries 26
List of Figures
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
